Trial Profile
A Randomized Placebo-Controlled Phase Ib/IIa Safety, Tolerability and Efficacy Study of Oral Phenoxodiol in Combination With Docetaxel Versus Docetaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary) ; Docetaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 31 Mar 2017 Status changed from recruiting to discontinued.
- 22 Jan 2008 The expected final data collection date for the primary endpoint is 1 Jun 2008 as reported by ClinicalTrials.gov.
- 23 Nov 2006 Status change